Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Q2 2020 Earnings Presentation
9 slides from Angiodynamics's earnings presentation, Jan 7, 2020
Slide 1: AngioDynamics Second Quarter 2020 Earnings Presentation
AngioDynamics Second Quarter 2020 Earnings Presentation January 7, 2020 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements Notice Regarding Forward-LookingStatements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, c
Slide 3: Second Quarter FY2020 Highlights
Second Quarter FY2020 Highlights Financial Performance Product Family Year-over-Year Sales Growth Q2 FY20 Q2 FY19 Change Vascular Interventions and Therapies (in millions) AngioVac® 53% Revenue $70.0 $70.0 0.0% Thrombolytic (10%) Core Peripheral 3% Revenue Excluding Asclera $70.0 $68.3 2.5% Venous I
Slide 4: Second Quarter FY2020 Results (unaudited)
Second Quarter FY2020 Results (unaudited) FY2020 FY2019 FY2020 FY2019 $ in thousands (except per share data) Q2 Results Q2 Results Change YTD Results YTD Results Change Revenue $70,003 $69,985 0.0%* $136,045 $133,928 1.6%* Vascular Interventions and Therapies 31,150 30,976 0.6%* 60,063 59,573 0.8%*
Slide 5: FY2020 Guidance
FY2020 Guidance Current Guidance (Unchanged) Revenue $280m - $286m Adjusted EPS $0.10 - $0.15 Gross Margin 58% - 59% 5
Slide 6: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 6
Slide 7: Reconciliation of GAAP to Non-GAAP Net Income and EPS
Reconciliation of GAAP to Non-GAAP Net Income and EPS Amounts in thousands (1) Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. (2) Deferred financing fees related to the o
Slide 8: Reconciliation of Net Income Adjusted EBITDA
Reconciliation of Net Income Adjusted EBITDA Amounts in thousands 8
Slide 9: Growth through Focus Execution Accountability
Growth through Focus Execution Accountability 9